18:57:11 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-08-26 Kvartalsrapport 2024-Q2
2024-04-19 Ordinarie utdelning DAC 0.00 DKK
2024-04-18 Årsstämma 2024
2024-03-25 Bokslutskommuniké 2023
2023-08-28 Kvartalsrapport 2023-Q2
2023-04-25 Ordinarie utdelning DAC 0.00 DKK
2023-04-24 Årsstämma 2023
2023-03-23 Bokslutskommuniké 2022
2022-08-29 Kvartalsrapport 2022-Q2
2022-04-28 Ordinarie utdelning DAC 0.00 DKK
2022-04-27 Årsstämma 2022
2022-03-28 Bokslutskommuniké 2021
2021-04-13 Ordinarie utdelning DAC 0.00 DKK
2021-04-12 Årsstämma 2021
2021-03-09 Bokslutskommuniké 2020
2020-04-21 Ordinarie utdelning DAC 0.00 DKK
2020-04-20 Årsstämma 2020
2020-03-20 Bokslutskommuniké 2019

Beskrivning

LandDanmark
ListaFirst North Denmark
SektorHälsovård
IndustriMedicinteknik
Danish Aerospace Company är verksamt inom IT-sektorn. Bolaget är en teknisk leverantör av produkter för satellit- och rymdsektorn, med en patenterad produktportfölj som huvudsakligen inkluderar träningsutrustning, biomedicinsk utrustning, tjänster för hälsoövervakning, samt vattenfiltreringsprodukter. Kunderna består av internationella rymdorganisationer. Verksamhet innehas på global nivå, med huvudkontor i Odense.
2023-03-23 16:34:05

COMPANY ANNOUNCEMENT

Odense, March 23rd, 2023

Company Announcement no. 41 - 23.03.2023      

Danish Aerospace Company A/S issues Annual Report for 2022

The Board of Directors of Danish Aerospace Company A/S (DAC) have today approved the audited annual report for 2022.

Key points from the 2022 Annual Report

  • Revenue has risen by 14% to DKK 23.3 million. (DKK 20.4 million in 2021)
  • EBITDA increased by 50% to DKK 3.36 million. (DKK 2.24 million in 2021)
  • Profit for the year grew to DKK 1.87 million (DKK 175 thousand in 2021)
  • DAC won a large contract with Axiom Space, Inc. which has the first private commercial contract with NASA to operate on the International Space Station (ISS). DAC has hereby taken the lead in providing exercise equipment for commercially selected astronauts and is very well positioned for growth in the commercial human spaceflight market.
  • ESA extended DAC’s contract in support of health monitoring on ISS and executed options in the contract for the coming years.
  • DAC has been allotted a significant part of the available test time for Andreas Mogensen’s next flight to ISS in 2023. In this connection DAC received approval to conduct three technological experiments, which will strengthen developments in our product portfolio going forward.
  • ESA initiated a new contract with DAC and Aquaporin Space Alliance ApS for further development of Aquaporin Inside water recovery technology for use in space.
  • DAC was selected to be a subcontractor to a project under the European Defense Fund -ABITS (Advanced Biometrics In Training and Simulation) -- to develop an in-door tactical training technology that integrates medical sensor feedback in the simulation environment.
  • DAC will receive the GAINTEX (Garments for Advanced INsight with TEXtiles) contract with ESA that is being transferred from the now bankrupt company Ohmatex. DAC will be the new prime contractor and pursue the project to completion.
  • The expectations for 2023 is a revenue of DKK 24-26 million; and an operating profit (EBITDA) of approx. DKK 3-4 million.

Management review

DAC realized earnings from operations before depreciation and amortization (EBITDA) of DKK 3.36 million. The DAC earnings before tax were DKK 2.59 million. The Company’s equity amounts to DKK 21.3 million as of December 31st, 2022.

In 2022, DAC entered the private commercial space market by signing a contract for exercise equipment with Axiom Space Inc. in January. The contract with Axiom was the result of several years of focused activities. This area has considerable further potential since four other private American consortia also plan to develop private commercial space stations. Accordingly, DAC is realizing one of its ambitious goals, which was set in connection with the IPO in 2019.

DAC has in 2022 completed the FERGO contract with the delivery of three completed FERGO flight ergometers and a training model for NASA. In 2023, NASA expects to launch two of the new FERGO ergometers to the International Space Station (ISS). Thus, four of DAC’s ergometers will be on board ISS (two of DAC’s original CEVIS ergometers will remain on board as back-up).

Development and manufacturing work on the multifunctional E4D exercise equipment for ESA and comparable exercise equipment for Axiom Space Inc., along with other contract activities is continuing as planned.

DAC has, on several occasions, received extensions and prolongations of this ESA contract for support of medical equipment and health monitoring of astronauts on the International Space Station, a contract that DAC has held since July 2006. The DAC team supports regular health monitoring and exercise tests on the International Space Station from the company’s control room in Odense, Denmark.

In pursuit of the second ‘pillar’ of DAC’s strategy outlined in its 2019 IPO – development of wearable technology for extreme environments on Earth – DAC is supporting the European Defense Fund’s ABITS (Advanced Biometrics In Training and Simulation) project. DAC’s role involves providing a medical sensor feedback capability to the new technology. Meanwhile DAC is continuing internal development work on a variety of new wearable sensors for health monitoring of astronauts and others in extreme environments.

Shortly before the end of the year, the company, in collaboration with its joint venture partner Aquaporin Space Alliance ApS, received a contract for further development of Aquaporin Inside Water Recovery technology for use in space.

In connection with Danish ESA Astronaut Andreas Mogensen’s upcoming six-month mission (named Huginn) to the International Space Station, the Danish Ministry of Higher Education and Science has approved three technological DAC experiments for implementation in 2023: (1) testing of the company’s wearable technology in space, (2) using virtual reality with DAC’s on-orbit exercise equipment and (3) testing of water recovery technologies for the Aquaporin Space Alliance. These experiment demonstrations will support the company’s efforts to mature new technologies for the growing commercial human space industry, as well as in development of technologies for extreme environments on Earth.

DAC passed this year’s annual supervisory audit, which is a check of the company’s AS/EN9100 standard rev. D quality control authorization by Bureau Veritas. DAC therefore continues to be one of few space companies in Denmark with this certification.

Expectations for the 2023 fiscal year.

Danish Aerospace Company continues to aggressively pursue its objectives in developing and providing innovative exercise and medical monitoring equipment for government and commercial human spaceflight activities and for terrestrial applications in extreme environments.

In the fiscal year 2023 Danish Aerospace Company’s expectations are:

  • Revenue of DKK 24-26 million; and
  • Operating profit (EBITDA) of approx. DKK 3-4 million.

General Assembly 2023  
DAC’s General Assembly will take place on April 24th, 2023. DAC will publish its interim report for 2023 on August 28th, 2023.

Attached to this document:
Appendix 1 – Key Figures
Appendix 2 – Changes in Equity 2022
Appendix 3 – Cash Flow 2022

The final annual report for 2022 will be available on the company’s website by March 27th, 2023, via the link below and attached

For further information, please contact:

Danish Aerospace Company A/S:

Chairman of the Board of Directors Niels Heering
Mobil: +45 40 17 75 31

CEO Thomas A.E. Andersen
Mobil: +45 40 29 41 62

Certified Adviser:

Baker Tilly Corporate Finance P/S
(CVR-nr. 40073310)
Poul Bundgaards Vej 1, 1.,
DK-2500 Valby
Tel.: +45 33 45 10 00
www.bakertilly.dk

About Danish Aerospace Company A/S:

Danish Aerospace Company is a high-tech company operating in the area of advanced medical instrumentation and other engineering fields primarily within space applications. Our products are based on many years of specialized research and development. These consist of developing, integrating, and applying new as well as established medical technologies to the challenges of functioning and remaining reliable in space. These products and services bring the potential of space research and experience from space operations down to Earth for the benefit of all Mankind.

Danish Aerospace Company employs engineers and technicians who deliver full engineering, production and technical services for our customers. We have specialized in customer specific design, development, manufacturing, certification, maintenance, testing, and operations.

The company has developed five generations respiratory equipment for spaceflight, bicycle ergometers for astronauts, countermeasures, adapted several commercial medical equipment for spaceflight and has participated in the development of the minus eighty-degree Celsius freezers.

The Company’s quality system is certified in obligation to BS EN ISO 9001:2015, BS EN 9100:2018 technical equivalent to AS9100D that is the acknowledged standard in the area.

Note: This is a translation of the corresponding Company Announcement in Danish. In case of discrepancies between the Danish wording and the English translation, the Danish wording prevails.

Appendix 1 – Key figures

 2022                           2021
2020
 
Key gures (DKK000)     
Revenue23,23420,35422,072  
Gross profit/loss18,09815,63816,891  
Other Operating Income67700  
EBITDA3,3582,2363,019  
Operating profit/loss2,5901,1011,538  
Net financials656(116)(374)  
Profit/loss for the year1,865175233  
Total assets36,00528,17031,487  
Equity21,30619,72719,869  


Ratios
     
Gross margin (%)77.8976.8376.53  
EBITDA margin (%)14.4510.9913.68  
Equity ratio (%)



Share performance

Earnings per share (DKK)


P/E ratio

P/B ratio

Total number of shares

No. of shares (on average)

Closing share price (DKK)
59.18






0.17


24.10

2.11

10,908,330

10,908,330

4.12
70.03





0.02

304.95

2.71

10,908,330

10,908,330

4.90
63.10





0.02

285.17

3.37

10,908,330

10,908,330

6.10
  

Appendix 2 – Changes in Equity 2022

  Reserve for  
ContributeddevelopmentRetained
capitalexpenditureearningsTotal
DKKDKKDKKDKK
Equity beginning of year1,090,833824,73517,810,94719,726,515
Exchange rate adjustments00(284,947)(284,947)
Transfer to reserves0228,121(228,121)0
Profit/loss for the year001,864,6581,864,658
Equity end of year1,090,8331,052,85619,162,53721,306,226

Appendix 3 – Cash flow 2022

Operating profit/loss 2,589,8751,101,247
Amortisation, depreciation and impairment losses

Working capital changes

Cash ows from ordinary operating activities




13
767,855

(10,416,241)

(7,058,511)
1,134,370

4,938,509

7,174,126

Financial income received

Financial expenses paid

Taxes refunded/(paid)

Cash ows from operating activities
 
702,589

(46,428)

31,807

(6,370,543)

243,986

(359,901)

554,026

7,612,237

Acquisition etc. of intangible assets

Acquisition etc. of property, plant and equipment

Cash ows from investing activities
 
(856,520)

(255,564)

(1,112,084)

(329,911)

(270,650)

(600,561)

Free cash ows generated from operations and investments before nancing
 
(7,482,627)

7,011,676

Loans raised
 
4,906,187

0
Repayments of loans etc.

Cash ows from nancing activities
 0

4,906,187
(4,486,867)

(4,486,867)

Increase/decrease in cash and cash equivalents
 
(2,576,440)

2,524,809

Cash and cash equivalents beginning of year

Cash and cash equivalents end of year
 
2,682,873

106,433

158,064

2,682,873

Cash and cash equivalents at year-end are composed of: Cash

Cash and cash equivalents end of year
 

106,433

106,433


2,682,873

2,682,873